.
Search
Dr. Neha Pagidipati and Dr. C. Michael Gibson discuss how the new lipid guidelines are moving the needle on LDL lowering: earlier, lower, longer.
The recent Vesalius trial adds to the data supporting lower is better, and suggests that even lower (an achieved LDL of 45 […]
Dr. Will Gibson and Dr. C. Michael Gibson discuss how p53 was once considered an undruggable target for cancer therapy.
A new article in the NEJM raises hope that there may be a path forward. Dr. Will Gibson, an oncologist at […]
Dr. Nihar Desai and I discuss how practice is moving toward
We talk about the importance of MDs reviewing AI output and the timing of CT reassessment of risk Sponsored by […]
Dr. Brittany Weber and Dr. C. Michael Gibson discuss: Why Atherosclerosis is All That Really Matters: A Summary for Seamless Integration into Daily Clinical Practice
Sponsored by Cleerly, Women as One and International Atherosclerosis Society.
Dr. Mike Sharma and Dr. C. Michael Gibson discuss the results of the phase III OCEANIC-STROKE Trial
In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by […]
Dr. Roxana Mehran and Dr. C. Michael Gibson discuss: Unmet Needs in Coronary Atherosclerosis: A Discussion of Clinical Trial Designs for Evaluation of Asymptomatic and Symptomatic Patients
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Karim Al-Azizi and Dr. C. Michael Gibson discuss: Caveat Emptor: Advantages and Disadvantages of Current Generation Tools for Evaluation of Coronary Atherosclerosis
Sponsored by Cleerly, Women as One and International Atherosclerosis Society